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Introduction
Decision analysis
The benefits of decision analysis to clinical practice
have been advocated for several years.1,2 It is a means
of synthesising evidence quantitatively to model the
risks and benefits of complex decisions. This can
clarify decision options, focus thinking and identify a
recommended course of action.
The feasibility of conducting a decision analysis in
general practice, however, has been questioned.3–5
Models are ideally tailored to individual patients and
incorporate their unique characteristics and prefer-
ences, but this is a time-consuming process. Primary
care can rarely afford the time required to elicit all the
factors necessary for such individualised analysis.
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ABSTRACT
Objective To develop and evaluate in primary care
a computerised decision support system for the
management of stroke patients based upon ‘patient
profile decision analysis’.
Design The decision support system incorporated
the findings of 960 Markov models examining 
the decision to prescribe aspirin in the secondary
prevention of stroke. The models reflected each
combination of nine risk factors that determined a
patient’s profile. The evaluation comprised a qual-
itative interview and a questionnaire administered
before and after the general practitioners (GPs)
were given access to the support system.
Setting Primary care.
Participants 15 GPs from the West Midlands.
Main outcome measures Decision certainty scor-
ing of hypothetical patient vignettes. Qualitative
perceptions of the applicability and acceptability of
the system for primary care.
Results After using the system, GPs were more cer-
tain of their decision making and made decisions
more in line with national guidelines. Quantitative
results further suggested that the system made
decision making easier, improved feelings of being
supported, improved the quality of decision making
and increased satisfaction. Qualitative themes
included that GPs thought the system could clarify
their own decision making and improve GP–patient
dialogue.
Conclusions The feasibility of individualised
decision analysis for general practice has been ques-
tioned. Patient profile decision analysis, however,
may be a valuable means of harnessing some of the
advantages of the methodology to produce more
patient-specific guidelines for primary care.
Keywords: decision analysis, decision support,
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However, general practice does use decision support
systems that provide guidance tailored towards groups
of patients with particular characteristics or profiles,
such as Sheffield tables for the primary prevention of
coronary heart disease.6 So can decision analysis based
upon ‘patient profiles’ rather than individuals be
useful to general practitioners (GPs)? Could this offer
a practical middle ground between pure individual
decision analysis and population-level risk assess-
ment? Modelling decisions for patient profiles and
using general utility values may not be individualised
decision analysis, but it is nevertheless a movement
towards more patient-focused decision making.
We sought to test whether patient profile decision
analysis could provide valuable guidance to primary
care. We modelled aspirin prescribing in the second-
ary prevention of stroke for 960 patient profiles to
calculate quality adjusted life years (QALY)-based
prescribing recommendations and other risk informa-
tion. We then developed a computerised support system
as an interface to enable GPs to access the results
quickly in a consultation. Prophylactic aspirin for
stroke patients was selected as a study focus because
prescribing in primary care has been consistently
reported to be sub-optimal despite aspirin being the
backbone of secondary prevention strategies around
the world.7–13 Research has also indicated that guid-
ance was required at a more patient-specific level.14 
Methods
The underlying decision model 
Markov models were developed for 960 different
patient profiles. Each model examined the decision 
to ‘prescribe’/‘not prescribe’ aspirin and utilised
evidence relating to that profile. All but one set of
model values were identified following a compre-
hensive search of the literature and where possible
were taken from systematic reviews or meta-analyses.
The unique risks of a stroke for patients of each
defined profile were calculated from primary analysis
of the General Practice Research Database (GPRD).
The GPRD is the world’s largest computerised dataset
of anonymised longitudinal patient records.15
The 960 profiles account for each combination 
of nine salient risk factors. These included age, time
since onset of first stroke, gender, diabetes, hyper-
tension and concurrent non-aspirin non-steroidal
anti-inflammatory drug (NSAID) use. The profiles
sought to reflect factors important to decision making
as identified by the literature and by clinicians ad-
vising the project. Other key factors were considered,
but these could not be included due to the limitations
of the available data (for example, the incomplete
recording of smoking status within GPRD and
methodological issues of combining factors from
different studies).
Figure 1 outlines the components of the decision
model. Consistent with other studies, we modelled the
prescribing decision for 12 months.16 After this time
period, users of the system could reassess the decision
for patients in light of any changes to their profile, for
example, age, risk factors.
The computerised decision support
system (CDSS)
Having generated a database of risk data for each
patient profile, a practical CDSS was developed. This
was designed to assist GP decision making and help
facilitate GP–patient dialogue.
The system was developed as a self-executing file
that could be distributed on a standard floppy disk 
or CD-ROM and installed as a desktop icon. The
program offers GPs an initial screen from which they
are required to select the desired patient profile from
drop-down menus, such as diabetes (‘Yes’ or ‘No’).
Having selected the profile, the user can then choose
from multiple screen options for instant access to 
the information that they require. Options include a
prescribing recommendation screen that gives a
recommended course of action plus explicit risk and
benefit information for the unique profile selected.
Users can also choose screens with more detailed risk
information, including the data presented in a variety
of formats such as numerical, graphical or pictorial
options (see Figure 2).
All stages of development were subject to an
iterative consultation process. This included eliciting
opinions on the model data generated, the CDSS
design and its content. Those consulted included clin-
icians from primary and secondary care, researchers
with a specialist interest in stroke medicine and lay
individuals.
Evaluation of the decision support
system 
After approval from the local research ethics committee,
a preliminary evaluation was conducted among 15
GPs from nine practices in North Staffordshire. The
practices comprise a research network established by
the Department of Medicines Management, Keele
University. All 45 GPs from the network were invited
to participate. Table 1 outlines the characteristics of
the sample.
First, each practitioner completed an initial ques-
tionnaire before being given a demonstration of
the CDSS and being allowed to familiarise themselves
with the system. Participants were encouraged to take
as long as they needed. One of the authors (DS) was
present to answer any questions throughout the
evaluation. On average, practitioners felt confident 
to use the system within five minutes. Each was then
asked to complete a second questionnaire while having
access to the system. Once completed, individuals were
then interviewed by DS using a topic guide informed
by a review of published studies and a pilot interview
with a GP. The whole evaluation process lasted between
60 and 90 minutes.
The questionnaires explored GPs’ views about
decision making. First, decision certainty in prescribing
aspirin was examined by exploring GPs’ choice predis-
position. Each questionnaire requested practitioners to
consider the same ten prescribing scenarios. These
described hypothetical stroke patients with com-
plicating co-morbidity that could feasibly present in
general practice. For each ‘vignette’, the GP was asked
to indicate on a 15-point Likert scale how likely they
would be to prescribe aspirin. The scale was anchored
by the options ‘yes aspirin’ and ‘no aspirin’, with
‘unsure’ at the midpoint. This was adapted from the
Choice Predisposition scale developed by the Ottawa
Health Research Institute.17
Nine vignettes were considered to be definite pro-
aspirin cases according to the Royal College of
Physicians’ National Guidelines for Stroke, while one
included an absolute contraindication to prescribing.
Decisions with clear optimum prescribing decisions
according to national guidelines were used so that
responses before and after having access to the model
and its data could be compared against a definite
outcome.
To further assess uncertainty, each questionnaire
also explored GPs’ decision conflict and practitioners
were asked to indicate their level of agreement with
six statements. These were to be considered in the
context of the decisions they had made about the ten
vignettes. The statements were adapted from the
Decision Conflict scale also developed by the Ottawa
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Figure 1 Components of the decision model
Model values varying
with each profile
 Risk of recurrent stroke
 Risk of major gastrointestinal bleed
 Risk of non-stroke death 
Fixed model values for all
 profiles
 Effectiveness of aspirin
 Severity of recurrent stroke
 Patient utility values
Output
 Prescribing recommendations
(based upon QALYs)
 Detailed risks and benefits of
prescribing for 960 different
profiles
Markov
Process
Health Research Institute. Responses were recorded
on a five-point Likert scale from 1 (‘strongly disagree’)
to 5 (‘strongly agree’). Both Ottawa scales were chosen
as the basis of the data as they have high test–retest 
co-efficients, have been shown to be sensitive to change
and have been tested in multiple clinical settings.17 
Finally, to further examine any effect of the decision
support system on decision making, practitioners
were asked further purposive questions in the second
questionnaire.
The final part of the evaluation was a qualitative
interview. The topic guide developed by the authors
served as a prompt for the interviewer to cover key
areas. These included perceived advantages and
disadvantages of using the system in practice, barriers
to use in a consultation, and the likelihood of use in a
consultation for their own information and/or shared
decision making with patients. All interviews were
tape-recorded and transcribed verbatim with consent.
Transcripts were analysed by all authors for major
themes through an iterative process of comparison
and evaluation. Each were revisited and revised as
further data were gathered. Emergent themes were
examined and their significance explored with
practitioners.18,19
Results
Qualitative interview results
Detailed results of the qualitative interviews will be
reported elsewhere. However, practitioners were very
positive about the potential for the CDSS to address
uncertainty among GPs. Comments ranged from the
system’s ability to clarify risks to the provision of
reassurance for GPs:
‘It is very reassuring to have the evidence in there . . .
sometimes I wonder, is my opinion based upon
evidence?’ GP11
‘I think [the CDSS] would be really helpful and I would
feel on much firmer ground.’ GP09
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Figure 2 One of the computerised decision support system’s risk information screens
Table 1 Characteristics of evaluation GPs 
Gender:
male n=13
female n=2
Age (years) Mean 45
Range 34–59
GP principals n=15
Number of years practising Mean = 16
Range 6–34
Number of partners in Mean = 4
their practice Range 1–8
Number recording consultation n=15
notes on their computer
‘It is helpful in that it reminds me that the risk of stroke
goes up substantially as you get older so your benefit
increases.’ GP03
Practitioners also cited several other potential benefits
of the system, including helping them to improve GP–
patient dialogue and reinforcing their recommendation
message to patients.
The applicability and acceptability of incorporating
the system into a primary care consultation is para-
mount to the value of such a tool. Again, this received
positive feedback:
‘This is the kind of thing you would want to have in the
consultation . . . you get immediate feedback on your
[prescribing] concerns, you immediately get reassurance
that this is the right course of action, and you can explain
it to the patient . . . you can even print it off for them –
a copy into the medical records, a copy to give to 
the patient so that they can study it further and show it
to all their various relatives . . . I think it has a lot of
potential.’ GP04
Almost all GPs also found the system very easy to use
and to navigate through the data screens available:
‘You can pick it up in two minutes! Anyone who is
computer literate.’ GP07
The time to access the system is another key issue
when examining how well it can be incorporated into
a consultation. As the system is almost instant to load
and is immediately presented once the desktop icon is
double-clicked, this was seen as a positive factor to its
potential use:
‘You want them to come up in 20–30 seconds. That will
. . . so you can do it mid-consultation.’ GP07 
‘Compared to other ones it is quick. You don’t have a lot
of time in consultations to plug in endless bits of data,
but something like this you could do in a minute . . . I
don’t think you can get any better than that and it is a lot
better than any of the other ones that I have used. You
are asking a specific question and you get the answer to
your question in just a few mouse clicks.’ GP04
‘It’s quick enough definitely. The only people who 
would struggle are people who are unhappy at using a
mouse.’ GP15
Furthermore, GPs liked the fact that the system could
be stored as a desktop icon. This was regarded as a
convenient source:
‘You haven’t got to load a floppy disk or a CD-ROM.’
GP01
Overall the interviewees regarded the system as
something that they could use within consultations.
However, several qualified their comments by
expressing reservations about this being incorporated
into any consultation of any GP. Issues such as prac-
titioners needing basic information technology (IT)
skills and both GPs and patients requiring an under-
standing of simple risk concepts are necessary. Limita-
tions to applicability of the system were therefore
identified.
Practitioners further qualified the value of the sys-
tem by stating that its potential lay with only certain
stroke patients. Potential use in clarifying decision
making for complex cases was one theme, while other
GPs described value for consultations in which patients
were unsure about taking aspirin:
‘If I had somebody who I was really unsure about, I
would use it.’ GP10
‘I would use it for those patients who express some
reservation about taking aspirin and where I am certain
that they need it . . . It would be a tool to help the patient
understand the risks and benefits. You often feel that you
are giving patients advice to take aspirin and they say
“yes”, but they go out of the door with no intention of
taking the drug because of their preconceived ideas. So if
you can help them overcome these misconceptions then
future compliance will be easier hopefully.’ GP01
Quantitative results
Choice predisposition vignette scoring
Analysis of changes in the choice predisposition scores
(that is, decision certainty) of the nine ‘pro-aspirin’
patient vignettes highlighted an improvement of
decision certainty with the system in line with
national guidelines. Across the nine vignettes there
was an overall shift towards ‘yes aspirin’ of 116 points
(1708 to 1824; maximum score = 2025) in the post-
demonstration results. This suggests that decision
making was made with greater certainty.
Decision conflict 
Results suggest that access to the system reduced de-
cision conflict for GPs (see Figure 3). Each statement
was framed positively in terms of confidence in decision
making and for all six there was a shift towards
‘strongly agree’ in the post-demonstration scores.
Overall, in a five-point Likert scale, results shifted by
37 points over the six statements.
Due to the small sample size, statistical tests on the
significance of the findings were not appropriate, but
the suggestion is that access to the decision support
system could have:
 improved feelings that decisions were supported
 made decision making easier
 improved feelings of being informed
 clarified decision values
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 improved the quality of decision making (feelings
of making informed decisions)
 increased satisfaction with decisions.
Purposive questioning
The additional questions included in the post-
demonstration questionnaire only provided further
indication that the CDSS had value in assisting GP
decision making (see Figure 4).
Overall, for the GPs taking part in the evaluation,
the majority were positive about its potential for
general practice. Eighty percent (n=12) said that they
would be ‘likely’ or ‘very likely’ to use it for their own
information if it were available, while 80% (n=12)
also said that they would be ‘likely’ or ‘very likely’ to
use it to share information with patients. More than
half of the GPs taking part in the evaluation (n=8)
also thought that the system could improve con-
cordance among patients ‘a lot’ or ‘a great deal’.
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Figure 3 Decision conflict results (1 = Strongly disagree; 5 = Strongly agree)
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Figure 4 Post-demonstration purposive question results 
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Discussion
This study has conducted a preliminary evaluation of
a computerised decision support system developed
for general practice. We used ‘patient profile decision
analysis’ as a means of enhancing the evidence base
available to clinicians and then designed the com-
puterised interface to present a range of risk data in 
a variety of different styles to suit the user. The aim
was to test the value of such an approach for general
practice.
Our results were positive and suggest that synthesis-
ing evidence in this way and framing these results in a
CDSS has value. This cannot offer the personalised
information that a pure individualised decision analysis
can, incorporating a patient’s own values, including
utilities. However, this study indicates that in seeking
a practical middle ground for time-pressured general
practice, there may be a role for our approach of pre-
calculating the findings of several profiles.
By predetermining the results of 960 profiles and
developing a user-friendly support system interface,
more patient-focused data than might otherwise be
available can be drawn upon by the GP. Our evaluation
suggests that this can clarify the risks and benefits of
prescribing, assist GP–patient dialogue and promote
shared decision making.
The positive results must nevertheless be context-
ualised. First, the findings are based upon a study of
15 GPs. This number of evaluation subjects influences
how the quantitative results can be interpreted and the
results can only therefore be an indication of possible
wider findings. The analysis that can be performed
upon data with such small numbers is very limited,
and this has been limited to descriptive tests. More
detailed evaluations involving greater numbers of
practitioners and also patients are necessary.
Secondly, potential bias arising from the individual
characteristics of subjects is particularly important to
recognise in evaluations with small numbers. A dif-
ferent demographic sample could significantly change
the scores and perspectives of the subjects, and this
must be acknowledged. For example, the data were
collected from GPs who were frequent users of IT in
primary care. The results may therefore not reflect
practitioners unfamiliar with computers and decision
support systems. The evaluation would have benefited
by the inclusion of some GPs with less exposure to IT.
One further limitation of the evaluation method-
ology is that decision making for hypothetical
vignettes may not accurately reflect decision making
for ‘real’ patients. Steps were taken to make the
vignettes as real as possible. No attempts were made to
restrict the vignette characteristics to the factors
covered by the model, and specific complicating areas
were included that were expected to highlight the
profile limitations of the system. This was thought the
most appropriate way of mimicking ‘real practice’ and
uncertainty that a GP with the system may encounter.
Any interpretation of the findings of the evaluation
is therefore limited, but the results to date are positive.
The evaluation was only an initial phase to test the
applicability and acceptability of such a system among
a limited number of GPs. Greater numbers of clin-
icians would be required to complete the evaluation
and the patient perspective is an essential viewpoint
that must also be incorporated.
The patient profile decision analysis approach may
have potential for primary care, especially in provid-
ing risk data. However, one concern of our approach
is that we have relied upon the use of generic utility
values rather than those of an individual patient when
calculating a recommendation. Models in which
utility values are sensitive would make it extremely
difficult to make such a recommendation with any
certainty. In our case this was less of a concern as
sensitivity analysis on the QALYs revealed the values
to be robust.
Conclusions
This study has demonstrated a means of incor-
porating some of the advantages of decision analysis
into a time-pressured general practice consultation
that has the potential for wider application. By with-
drawing the practical modelling phase from a con-
sultation and replacing it with predetermined
calculations in a user-friendly format, many of the
advantages of the methodology can be retained. New
information can then be made available to general
practice to inform decision makers.
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